B.M.J. Cantwell

1.5k total citations
52 papers, 1.1k citations indexed

About

B.M.J. Cantwell is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, B.M.J. Cantwell has authored 52 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 14 papers in Molecular Biology and 10 papers in Pulmonary and Respiratory Medicine. Recurrent topics in B.M.J. Cantwell's work include Estrogen and related hormone effects (9 papers), Cancer therapeutics and mechanisms (6 papers) and Neuroendocrine Tumor Research Advances (5 papers). B.M.J. Cantwell is often cited by papers focused on Estrogen and related hormone effects (9 papers), Cancer therapeutics and mechanisms (6 papers) and Neuroendocrine Tumor Research Advances (5 papers). B.M.J. Cantwell collaborates with scholars based in United Kingdom, United States and Australia. B.M.J. Cantwell's co-authors include Adrian L. Harris, J Carmichael, Mitch Dowsett, J. J. Fennelly, Garth Rapeport, S.L. Jeffcoate, Michael E. Jones, Alex Hendrick, J. Carmichael and Michael J. Duffy and has published in prestigious journals such as The Lancet, The Journal of Clinical Endocrinology & Metabolism and British Journal of Cancer.

In The Last Decade

B.M.J. Cantwell

52 papers receiving 997 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
B.M.J. Cantwell United Kingdom 19 421 338 172 159 138 52 1.1k
S. J. Harland United Kingdom 18 390 0.9× 398 1.2× 410 2.4× 135 0.8× 219 1.6× 32 1.1k
P. Dodion Belgium 20 446 1.1× 484 1.4× 101 0.6× 70 0.4× 204 1.5× 72 1.1k
David H. Moore United States 15 411 1.0× 647 1.9× 156 0.9× 141 0.9× 261 1.9× 34 1.3k
Pentti J. Taskinen Finland 16 465 1.1× 343 1.0× 69 0.4× 319 2.0× 235 1.7× 35 1.3k
Tsuyoshi Honda Japan 19 188 0.4× 394 1.2× 148 0.9× 86 0.5× 154 1.1× 66 1.1k
P.H.B. Willemse Netherlands 22 486 1.2× 339 1.0× 391 2.3× 140 0.9× 204 1.5× 62 1.4k
Ritva Valavaara Finland 14 293 0.7× 126 0.4× 78 0.5× 406 2.6× 134 1.0× 29 900
Theodotis Papageorgiou Greece 15 255 0.6× 220 0.7× 194 1.1× 55 0.3× 89 0.6× 52 955
A Capelli Italy 11 121 0.3× 151 0.4× 137 0.8× 147 0.9× 61 0.4× 34 774
M Soukop United Kingdom 19 575 1.4× 236 0.7× 215 1.3× 54 0.3× 169 1.2× 48 1.1k

Countries citing papers authored by B.M.J. Cantwell

Since Specialization
Citations

This map shows the geographic impact of B.M.J. Cantwell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by B.M.J. Cantwell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites B.M.J. Cantwell more than expected).

Fields of papers citing papers by B.M.J. Cantwell

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by B.M.J. Cantwell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by B.M.J. Cantwell. The network helps show where B.M.J. Cantwell may publish in the future.

Co-authorship network of co-authors of B.M.J. Cantwell

This figure shows the co-authorship network connecting the top 25 collaborators of B.M.J. Cantwell. A scholar is included among the top collaborators of B.M.J. Cantwell based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with B.M.J. Cantwell. B.M.J. Cantwell is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Millward, Michael, David R. Newell, Linus N. Igwemezie, et al.. (1995). Phase I and pharmacokinetic study of a water-soluble etoposide prodrug, etoposide phosphate (BMY-40481). European Journal of Cancer. 31(13-14). 2409–2411. 12 indexed citations
2.
Calvert, A H, Michael Lind, B.M.J. Cantwell, et al.. (1993). Long-term oral etoposide in metastatic breast cancer: clinical and pharmacokinetic results. Cancer Treatment Reviews. 19. 27–33. 30 indexed citations
3.
4.
Richardson, PG, et al.. (1992). Metastatic Melanoma to the Testis Simulating Primary Seminoma. British Journal of Urology. 69(6). 663–665. 7 indexed citations
5.
Hendrick, Alex, David Simmons, & B.M.J. Cantwell. (1992). Allergic reactions to carboplatin. Annals of Oncology. 3(3). 239–240. 37 indexed citations
6.
Hendrick, Alex, Adrian L. Harris, & B.M.J. Cantwell. (1991). Verapamil with mitoxantrone for advanced ovarian cancer: A negative phase II trial. Annals of Oncology. 2(1). 71–72. 21 indexed citations
7.
Thompson, Stephen, et al.. (1991). Abnormally-fucosylated haptoglobin: a cancer marker for tumour burden but not gross liver metastasis. British Journal of Cancer. 64(2). 386–390. 36 indexed citations
8.
Dowsett, Mitch, et al.. (1991). Low-dose aminoglutethimide in postmenopausal breast cancer: Effects on adrenal and thyroid hormone secretion. European Journal of Cancer and Clinical Oncology. 27(7). 846–849. 4 indexed citations
9.
Millward, M.J., Alex Hendrick, & B.M.J. Cantwell. (1990). Fixed dose short course mitomyucin C with vincristine in advanced pre-treated breast cancer. Annals of Oncology. 1(5). 373–374. 3 indexed citations
10.
Harris, Adrian L., J Carmichael, J R Farndon, et al.. (1990). Comparison of short-term and continuous chemotherapy (mitozantrone) for advanced breast cancer. The Lancet. 335(8683). 186–190. 70 indexed citations
11.
Thompson, Stephen, Emmett Tsz Yeung Wong, B.M.J. Cantwell, & G. A. Turner. (1990). Serum alpha- 1 -proteinase inhibitor with abnormal properties in ovarian cancer. Clinica Chimica Acta. 193(1-2). 13–25. 6 indexed citations
12.
Carmichael, J, B.M.J. Cantwell, Barry D. Zussman, et al.. (1989). A pharmacokinetic study of granisetron (BRL 43694A), a selective 5-HT3 receptor antagonist: correlation with anti-emetic response. Cancer Chemotherapy and Pharmacology. 24(1). 45–9. 82 indexed citations
13.
Dowsett, Mitch, B.M.J. Cantwell, & Adrian L. Harris. (1989). Endocrinology of Zoladex in Postmenopausal Women. Hormone Research. 32(1). 209–212. 1 indexed citations
14.
Cantwell, B.M.J. & Adrian L. Harris. (1988). The efficacy of 5-fluorouracil in human colorectal cancer is not enhanced by thymidylate synthetase inhibition with CB3717 (N10-propargyl-5,8 dideazafolic acid). British Journal of Cancer. 58(2). 189–190. 4 indexed citations
15.
Veale, D, J Carmichael, B.M.J. Cantwell, et al.. (1988). A phase 1 and pharmacokinetic study of didox: A ribonucleotide reductase inhibitor. British Journal of Cancer. 58(1). 70–72. 37 indexed citations
16.
Skillen, A. W., et al.. (1988). Urinary protein and enzyme excretion in patients receiving chemotherapy with the cis-platinum analogs carboplatin (CBDCA, JM8) and iproplatin (CHIP, JM9). Cancer Chemotherapy and Pharmacology. 22(3). 228–234. 5 indexed citations
17.
Dowsett, Mitch, et al.. (1988). Suppression of Postmenopausal Ovarian Steroidogenesis With the Luteinizing Hormone-Releasing Hormone Agonist Goserelin*. The Journal of Clinical Endocrinology & Metabolism. 66(4). 672–677. 78 indexed citations
18.
Cantwell, B.M.J., et al.. (1988). Thromboses and thromboemboli in patients with lymphoma during cytotoxic chemotherapy.. BMJ. 297(6642). 179–180. 11 indexed citations
19.
20.
Cantwell, B.M.J., et al.. (1986). Phase II study of a novel antifolate, N10-propargyl-5,8 dideazafolic acid (CB3717), in malignant mesothelioma.. PubMed. 70(11). 1335–6. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by S. J. Harland Breakdown of academic impact, for papers by P. Dodion Breakdown of academic impact, for papers by David H. Moore Breakdown of academic impact, for papers by Pentti J. Taskinen Breakdown of academic impact, for papers by Tsuyoshi Honda Breakdown of academic impact, for papers by P.H.B. Willemse Breakdown of academic impact, for papers by Ritva Valavaara Breakdown of academic impact, for papers by Theodotis Papageorgiou Breakdown of academic impact, for papers by A Capelli Breakdown of academic impact, for papers by M Soukop
Rankless by CCL
2026